Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Velinotamig specified

Bispecific antibody · Immune activation, directed at B-cell maturation antigen (TNFRSF17) and CD3 (CD3E) · developed by Cullinan Therapeutics

Phase 1/2 Most advanced trial
CGEM Developer
1 Registered trials

What is Velinotamig specified?

Velinotamig is an engineered bispecific antibody that binds BCMA and CD3. It is being studied in immune thrombocytopenia and warm autoimmune hemolytic anemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
B-cell maturation antigen (TNFRSF17), CD3 (CD3E)
Mechanism
Immune activation, directed at B-cell maturation antigen (TNFRSF17) and CD3 (CD3E)
Therapy area
Hematology, Immunology
Developer
Cullinan Therapeutics Inc. (CGEM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07738822 Phase 1/2 Immune Thrombocytopenia (ITP) Not yet recruiting CGEM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Immune Thrombocytopenia (ITP)Warm Autoimmune Hemolytic Anemia (WAIHA)

Other drugs acting on TNFRSF17 / CD3E

More from Cullinan Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEM page.

Follow CGEM, the company behind Velinotamig specified

See CGEM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CGEM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.